Gastaldelli Amalia, Gaggini Melania, DeFronzo Ralph
aCardiometabolic Risk Laboratory, Institute of Clinical Physiology, National Research Council, Pisa, Italy bUniversity of Texas Health Science Center at San Antonio, TX, USA.
Curr Opin Clin Nutr Metab Care. 2017 Jul;20(4):300-309. doi: 10.1097/MCO.0000000000000384.
Glucagon and GLP-1 share the same origin (i.e., proglucagon); primarily GLP-1 is generated from intestinal L-cells and glucagon from pancreatic α-cell, but intestinal glucagon and pancreatic GLP-1 secretion is likely. Glucose kinetics are tightly regulated by pancreatic hormones insulin and glucagon, but other hormones, including glucagon-like peptide-1 (GLP-1), also play an important role. The purpose of this review is to describe the recent findings on the mechanisms by which these two hormones regulate glucose kinetics.
Recent findings showed new important mechanisms of action of glucagon and GLP-1 in the regulation of glucose metabolism. Knock out of glucagon receptors protects against hyperglycemia without causing hypoglycemia. GLP-1 not only stimulates insulin secretion, but it has also an independent effect on the liver and inhibits glucose production. Moreover, when coinfused with glucagon, GLP-1 limits the hyperglycemic effects. Both hormones have also central effects on gastric emptying (delayed), intestinal motility (reduced), and satiety (increased).
The implications of these findings are very important for the management of type 2 diabetes given that GLP-1 receptor agonist are currently approved for the treatment of hyperglycemia and glucagon receptor antagonists and GLP-1/glucagon dual agonists are under development.
胰高血糖素和胰高血糖素样肽-1(GLP-1)起源相同(即前胰高血糖素);主要地,GLP-1由肠道L细胞产生,胰高血糖素由胰腺α细胞产生,但肠道胰高血糖素和胰腺GLP-1的分泌也有可能。葡萄糖动力学受到胰腺激素胰岛素和胰高血糖素的严格调控,但包括GLP-1在内的其他激素也发挥着重要作用。本综述的目的是描述这两种激素调节葡萄糖动力学机制的最新研究发现。
最新研究发现显示了胰高血糖素和GLP-1在调节葡萄糖代谢方面新的重要作用机制。敲除胰高血糖素受体可预防高血糖而不引起低血糖。GLP-1不仅刺激胰岛素分泌,而且对肝脏有独立作用并抑制葡萄糖生成。此外,当与胰高血糖素共同输注时,GLP-1可限制高血糖作用。这两种激素对胃排空(延迟)、肠道蠕动(减弱)和饱腹感(增强)也有中枢作用。
鉴于GLP-1受体激动剂目前已被批准用于治疗高血糖,且胰高血糖素受体拮抗剂和GLP-1/胰高血糖素双重激动剂正在研发中,这些研究发现对于2型糖尿病的管理具有非常重要的意义。